date,text,url,form,accepted_time
2020-07-31," 8-k 1 nc10013869_8k.htm 8-k united states securities and exchange commission washington, dc 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of report (date of earliest event reported): july 31, 2020 arya sciences acquisition corp ii (exact name of registrant as specified in its charter) cayman islands 001-39311 98-1533670 (state or other jurisdiction of incorporation) (commission file number) (i.r.s. employer identification no.) 51 astor place, 10th floor new york, ny 10003 (address of principal executive offices) (zip code) (212) 284-2300 registrant’s telephone number, including area code not applicable (former name or former address, if changed since last report) check the appropriate box below if the form 8-k filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☒ written communications pursuant to rule 425 under the securities act (17 cfr 230.425) ☐ soliciting material pursuant to rule 14a-12 under the exchange act (17 cfr 240.14a-12) ☐ pre-commencement communications pursuant to rule 14d-2(b) under the exchange act (17 cfr 240.14d-2(b)) ☐ pre-commencement communications pursuant to rule 13e-4(c) under the exchange act (17 cfr 240.13e-4(c)) securities registered pursuant to section 12(b) of the act: title of each class trading symbol(s) name of each exchange on which registered units, each consisting of one class a ordinary share, $0.0001 par value, and one-third of one redeemable warrant arybu the nasdaq capital market class a ordinary shares included as part of the units aryb the nasdaq capital market redeemable warrants included as part of the units, each whole warrant exercisable for one class a ordinary share at an exercise price of $11.50 arybw the nasdaq capital market indicate by check mark whether the registrant is an emerging growth company as defined in rule 405 of the securities act of 1933 or rule 12b-2 of the securities exchange act of 1934. emerging growth company ☒ if an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the exchange act. ☐ item 7.01 regulation fd disclosure. on july 30, 2020, arya sciences acquisition corp ii (“arya”) announced a proposed business combination (the “business combination”) between arya and cerevel therapeutics, inc. (“cerevel”). on july 31, 2020, tony coles, m.d., the chief executive officer and chairperson of the board of directors of cerevel, appeared on an interview with cnbc to discuss the business combination. attached as exhibit 99.1 to this current report on form 8-k and incorporated into this item 7.01 by reference is a transcript of such interview. a copy of the business combination agreement (as it may be amended, supplemented or otherwise modified from time to time, the “business combination agreement”), by and among arya, cassidy merger sub 1, inc. and cerevel, related to the business combination was attached as exhibit 2.1 to arya’s current report on form 8-k filed with the securities and exchange commission (“sec”) on july 30, 2020. the foregoing (including exhibit 99.1) is being furnished pursuant to item 7.01 and will not be deemed to be filed for purposes of section 18 of the securities and exchange act of 1934, as amended (the “exchange act”), or otherwise be subject to the liabilities of that section, nor will it be deemed to be incorporated by reference in any filing under the securities act of 1933, as amended (the “securities act”) or the exchange act. additional information in connection with the business combination, arya intends to file with the u.s. securities and exchange commission’s (“sec”) a registration statement on form s-4 (the “registration statement”), which will include a preliminary prospectus and preliminary proxy statement. arya will mail a definitive proxy statement/final prospectus and other relevant documents to its shareholders. this communication is not a substitute for the registration statement, the definitive proxy statement/final prospectus or any other document that arya will send to its shareholders in connection with the business combination. investors and security holders of arya are advised to read, when available, the proxy statement/prospectus in connection with arya’s solicitation of proxies for its extraordinary general meeting of shareholders to be held to approve the business combination (and related matters) because the proxy statement/prospectus will contain important information about the business combination and the parties to the business combination. the definitive proxy statement/final prospectus will be mailed to shareholders of arya as of a record date to be established for voting on the business combination. shareholders will also be able to obtain copies of the proxy statement/prospectus, without charge, once available, at the sec’s website at www.sec.gov or by directing a request to: 51 astor place, 10th floor, new york, new york 10003. participants in the solicitation arya, cerevel and their respective directors, executive officers, other members of management, and employees, under sec rules, may be deemed to be participants in the solicitation of proxies of arya’s shareholders in connection with the business combination. investors and security holders may obtain more detailed information regarding the names and interests in the business combination of arya’s directors and officers in arya’s filings with the sec, including the registration statement to be filed with the sec by arya, which will include the proxy statement of arya for the business combination, and such information and names of cerevel’s directors and executive officers will also be in the registration statement to be filed with the sec by arya, which will include the proxy statement of arya for the business combination. forward looking statements certain statements made herein are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the private securities litigation reform act of 1995. forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. these forward-looking statements include, but are not limited to, statements regarding future events, the business combination between arya and cerevel, the estimated or anticipated future results and benefits of the combined company following the business combination, including the likelihood and ability of the parties to successfully consummate the business combination, future opportunities for the combined company, and other statements that are not historical facts. these statements are based on the current expectations of arya’s management and are not predictions of actual performance. these forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. actual events and circumstances are difficult or impossible to predict and will differ from assumptions. many actual events and circumstances are beyond the control of arya and cerevel. these statements are subject to a number of risks and uncertainties regarding arya’s businesses and the business combination, and actual results may differ materially. these risks and uncertainties include, but are not limited to, general economic, political and business conditions; the inability of the parties to consummate the business combination or the occurrence of any event, change or other circumstances that could give rise to the termination of the business combination agreement; the outcome of any legal proceedings that may be instituted against the parties following the announcement of the business combination; the receipt of an unsolicited offer from another party for an alternative business transaction that could interfere with the business combination; the risk that the approval of the shareholders of arya or cerevel for the potential transaction is not obtained; failure to realize the anticipated benefits of the business combination, including as a result of a delay in consummating the potential transaction or difficulty in integrating the businesses of arya and cerevel; the risk that the business combination disrupts current plans and operations as a result of the announcement and consummation of the business combination; the ability of the combined company to grow and manage growth profitably and retain its key employees; the amount of redemption requests made by arya’s shareholders; the inability to obtain or maintain the listing of the post-acquisition company’s securities on nasdaq following the business combination; costs related to the business combination; and those factors discussed in arya’s final prospectus relating to its initial public offering, dated june 4, 2020, and other filings with the sec. there may be additional risks that arya presently does not know or that arya currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. in addition, forward-looking statements provide arya’s expectations, plans or forecasts of future events and views as of the date of this communication. arya anticipates that subsequent events and developments will cause arya’s assessments to change. however, while arya may elect to update these forward-looking statements at some point in the future, arya specifically disclaims any obligation to do so. these forward-looking statements should not be relied upon as representing arya’s assessments as of any date subsequent to the date of this communication. accordingly, undue reliance should not be placed upon the forward-looking statements. disclaimer this communication is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities or the solicitation of any vote in any jurisdiction pursuant to the business combination or otherwise, nor shall there be any sale, issuance or transfer or securities in any jurisdiction in contravention of applicable law. no offer of securities shall be made except by means of a prospectus meeting the requirements of section 10 of the securities act. item 9.01 financial statements and exhibits. (d) exhibits exhibit number description 99.1 transcript of interview, dated july 31, 2020. signature pursuant to the requirements of the securities exchange act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. dated: july 31, 2020 arya sciences acquisition corp ii by: /s/ adam stone name: adam stone title: chief executive officer ",https://www.sec.gov/Archives/edgar/data/1805387/000114036120017184/0001140361-20-017184-index.htm,8-K,2020-07-31 17:03:46
2020-07-30," 8-k 1 nc10013869.htm 8-k united states securities and exchange commission washington, dc 20549 _______________________ form 8-k _______________________ current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of report (date of earliest event reported): july 30, 2020 _______________________ arya sciences acquisition corp ii (exact name of registrant as specified in its charter) _______________________ cayman islands 001-39311 98-1533670 (state or other jurisdiction of incorporation) (commission file number) (i.r.s. employer identification no.) 51 astor place, 10th floor new york, ny 10003 (address of principal executive offices) (zip code) (212) 284-2300 registrant’s telephone number, including area code not applicable (former name or former address, if changed since last report) _______________________ check the appropriate box below if the form 8-k filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☒ written communications pursuant to rule 425 under the securities act (17 cfr 230.425) ☐ soliciting material pursuant to rule 14a-12 under the exchange act (17 cfr 240.14a-12) ☐ pre-commencement communications pursuant to rule 14d-2(b) under the exchange act (17 cfr 240.14d-2(b)) ☐ pre-commencement communications pursuant to rule 13e-4(c) under the exchange act (17 cfr 240.13e-4(c)) securities registered pursuant to section 12(b) of the act: title of each class trading symbol(s) name of each exchange on which registered units, each consisting of one class a ordinary share, $0.0001 par value, and one-third of one redeemable warrant arybu the nasdaq capital market class a ordinary shares included as part of the units aryb the nasdaq capital market redeemable warrants included as part of the units, each whole warrant exercisable for one class a ordinary share at an exercise price of $11.50 arybw the nasdaq capital market indicate by check mark whether the registrant is an emerging growth company as defined in rule 405 of the securities act of 1933 or rule 12b-2 of the securities exchange act of 1934. emerging growth company ☒ if an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the exchange act. ☐ item 7.01 regulation fd disclosure. on july 30, 2020, arya sciences acquisition corp ii (“arya”) held a previously announced joint conference call (the “conference call”) with cerevel therapeutics, inc. (“cerevel”) to discuss the proposed business combination (the “business combination”) between arya and cerevel. attached as exhibit 99.1 to this current report on form 8-k and incorporated into this item 7.01 by reference is a transcript of the conference call. a copy of the business combination agreement (as it may be amended, supplemented or otherwise modified from time to time, the “business combination agreement”), by and among arya, cassidy merger sub 1, inc. and cerevel, related to the business combination was attached as exhibit 2.1 to arya’s current report on form 8-k filed with the securities and exchange commission (“sec”) on july 30, 2020. the foregoing (including exhibit 99.1) is being furnished pursuant to item 7.01 and will not be deemed to be filed for purposes of section 18 of the securities and exchange act of 1934, as amended (the “exchange act”), or otherwise be subject to the liabilities of that section, nor will it be deemed to be incorporated by reference in any filing under the securities act of 1933, as amended (the “securities act”) or the exchange act. additional information in connection with the business combination, arya intends to file with the u.s. securities and exchange commission’s (“sec”) a registration statement on form s-4 (the “registration statement”), which will include a preliminary prospectus and preliminary proxy statement. arya will mail a definitive proxy statement/final prospectus and other relevant documents to its shareholders. this communication is not a substitute for the registration statement, the definitive proxy statement/final prospectus or any other document that arya will send to its shareholders in connection with the business combination. investors and security holders of arya are advised to read, when available, the proxy statement/prospectus in connection with arya’s solicitation of proxies for its extraordinary general meeting of shareholders to be held to approve the business combination (and related matters) because the proxy statement/prospectus will contain important information about the business combination and the parties to the business combination. the definitive proxy statement/final prospectus will be mailed to shareholders of arya as of a record date to be established for voting on the business combination. shareholders will also be able to obtain copies of the proxy statement/prospectus, without charge, once available, at the sec’s website at www.sec.gov or by directing a request to: 51 astor place, 10th floor, new york, new york 10003. 2 participants in the solicitation arya, cerevel and their respective directors, executive officers, other members of management, and employees, under sec rules, may be deemed to be participants in the solicitation of proxies of arya’s shareholders in connection with the business combination. investors and security holders may obtain more detailed information regarding the names and interests in the business combination of arya’s directors and officers in arya’s filings with the sec, including the registration statement to be filed with the sec by arya, which will include the proxy statement of arya for the business combination, and such information and names of cerevel’s directors and executive officers will also be in the registration statement to be filed with the sec by arya, which will include the proxy statement of arya for the business combination. forward looking statements certain statements made herein are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the private securities litigation reform act of 1995. forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. these forward-looking statements include, but are not limited to, statements regarding future events, the business combination between arya and cerevel, the estimated or anticipated future results and benefits of the combined company following the business combination, including the likelihood and ability of the parties to successfully consummate the business combination, future opportunities for the combined company, and other statements that are not historical facts. these statements are based on the current expectations of arya’s management and are not predictions of actual performance. these forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. actual events and circumstances are difficult or impossible to predict and will differ from assumptions. many actual events and circumstances are beyond the control of arya and cerevel. these statements are subject to a number of risks and uncertainties regarding arya’s businesses and the business combination, and actual results may differ materially. these risks and uncertainties include, but are not limited to, general economic, political and business conditions; the inability of the parties to consummate the business combination or the occurrence of any event, change or other circumstances that could give rise to the termination of the business combination agreement; the outcome of any legal proceedings that may be instituted against the parties following the announcement of the business combination; the receipt of an unsolicited offer from another party for an alternative business transaction that could interfere with the business combination; the risk that the approval of the shareholders of arya or cerevel for the potential transaction is not obtained; failure to realize the anticipated benefits of the business combination, including as a result of a delay in consummating the potential transaction or difficulty in integrating the businesses of arya and cerevel; the risk that the business combination disrupts current plans and operations as a result of the announcement and consummation of the business combination; the ability of the combined company to grow and manage growth profitably and retain its key employees; the amount of redemption requests made by arya’s shareholders; the inability to obtain or maintain the listing of the post-acquisition company’s securities on nasdaq following the business combination; costs related to the business combination; and those factors discussed in arya’s final prospectus relating to its initial public offering, dated june 4, 2020, and other filings with the sec. there may be additional risks that arya presently does not know or that arya currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. in addition, forward-looking statements provide arya’s expectations, plans or forecasts of future events and views as of the date of this communication. arya anticipates that subsequent events and developments will cause arya’s assessments to change. however, while arya may elect to update these forward-looking statements at some point in the future, arya specifically disclaims any obligation to do so. these forward-looking statements should not be relied upon as representing arya’s assessments as of any date subsequent to the date of this communication. accordingly, undue reliance should not be placed upon the forward-looking statements. 3 disclaimer this communication is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities or the solicitation of any vote in any jurisdiction pursuant to the business combination or otherwise, nor shall there be any sale, issuance or transfer or securities in any jurisdiction in contravention of applicable law. no offer of securities shall be made except by means of a prospectus meeting the requirements of section 10 of the securities act. item 9.01 financial statements and exhibits. (d) exhibits exhibit number description 99.1 transcript of conference call, dated july 30, 2020. 4 signature pursuant to the requirements of the securities exchange act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. dated: july 30, 2020 arya sciences acquisition corp ii by: /s/ adam stone name: adam stone title: chief executive officer 5 ",https://www.sec.gov/Archives/edgar/data/1805387/000114036120017077/0001140361-20-017077-index.htm,8-K,2020-07-30 19:16:33
2020-07-30," 8-k 1 nc10013869x1_8k.htm form 8-k united states securities and exchange commission washington, dc 20549 _______________________ form 8-k _______________________ current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of report (date of earliest event reported): july 29, 2020 _______________________ arya sciences acquisition corp ii (exact name of registrant as specified in its charter) _______________________ cayman islands 001-39311 98-1533670 (state or other jurisdiction of incorporation) (commission file number) (i.r.s. employer identification no.) 51 astor place, 10th floor new york, ny 10003 (address of principal executive offices) (zip code) (212) 284-2300 registrant’s telephone number, including area code not applicable (former name or former address, if changed since last report) _______________________ check the appropriate box below if the form 8-k filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☒ written communications pursuant to rule 425 under the securities act (17 cfr 230.425) ☐ soliciting material pursuant to rule 14a-12 under the exchange act (17 cfr 240.14a-12) ☐ pre-commencement communications pursuant to rule 14d-2(b) under the exchange act (17 cfr 240.14d-2(b)) ☐ pre-commencement communications pursuant to rule 13e-4(c) under the exchange act (17 cfr 240.13e-4(c)) securities registered pursuant to section 12(b) of the act: title of each class trading symbol(s) name of each exchange on which registered units, each consisting of one class a ordinary share, $0.0001 par value, and one-third of one redeemable warrant arybu the nasdaq capital market class a ordinary shares included as part of the units aryb the nasdaq capital market redeemable warrants included as part of the units, each whole warrant exercisable for one class a ordinary share at an exercise price of $11.50 arybw the nasdaq capital market indicate by check mark whether the registrant is an emerging growth company as defined in rule 405 of the securities act of 1933 or rule 12b-2 of the securities exchange act of 1934. emerging growth company ☒ if an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the exchange act. ☐ item 1.01 entry into a material definitive agreement. business combination agreement on july 29, 2020, arya sciences acquisition corp ii, a cayman islands exempted company (“arya”), entered into a business combination agreement (as it may be amended, supplemented or otherwise modified from time to time, the “business combination agreement”), by and among arya, cassidy merger sub 1, inc., a delaware corporation (“cassidy merger sub”), and cerevel therapeutics, inc., a delaware corporation (“cerevel”). the business combination agreement and the transactions contemplated thereby were approved by the boards of directors of each of arya and cerevel. the business combination the business combination agreement provides for, among other things, the following transactions on the closing date: (i) arya will become a delaware corporation (the “domestication”) and, in connection with the domestication, (a) arya’s name will be changed to “cerevel therapeutics holdings, inc.”, (b) each outstanding class a ordinary share of arya and each outstanding class b ordinary share of arya will become one share of common stock of arya (the “arya common stock”), and (c) each outstanding warrant of arya will become one warrant to purchase one share of arya common stock; and (ii) following the domestication, cassidy merger sub will merge with and into cerevel, with cerevel as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of arya (the “merger”). the domestication, the merger and the other transactions contemplated by the business combination agreement are hereinafter referred to as the “business combination”. the business combination is expected to close in the fourth quarter of 2020, following the receipt of the required approval by arya’s stockholders and the fulfillment of other customary closing conditions. business combination consideration in accordance with the terms and subject to the conditions of the business combination agreement, (i) outstanding shares and vested equity awards of cerevel will be exchanged for shares of arya common stock or comparable equity awards that are settled or are exercisable for shares of arya common stock, as applicable, based on an implied cerevel equity value of $780,000,000, and (ii) all unvested equity awards of cerevel will be exchanged for comparable equity awards that are settled or exercisable for shares of arya common stock, determined based on the same implied cerevel equity value as described in clause (i). representations and warranties; covenants the business combination agreement contains representations, warranties and covenants of each of the parties thereto that are customary for transactions of this type. arya has also agreed to take all action within its power as may be necessary or appropriate such that, effective immediately after the closing of the business combination, the arya board of directors shall consist of ten directors, which shall be divided into three classes, which directors shall include the current board of directors of cerevel plus one individual to be mutually agreed between cerevel and arya and, at the sole discretion of cerevel, one additional individual. in addition, arya has agreed to adopt an equity incentive plan and employee stock purchase plan, as described in the business combination agreement. conditions to each party’s obligations the obligation of arya and cerevel to consummate the business combination is subject to certain closing conditions, including, but not limited to, (i) the expiration or termination of the applicable waiting period under the hart-scott-rodino antitrust improvements act of 1976, as amended, (ii) the approval of arya’s shareholders, (iii) the approval of cerevel’s shareholders and (iv) arya having at least $5,000,001 of net tangible assets (as determined in accordance with rule 3a51-1(g)(1) of the securities exchange act of 1934, as amended) remaining after the closing of the business combination. in addition, the obligation of cerevel to consummate the business combination is subject to the fulfillment of other closing conditions, including, but not limited to, (i) the aggregate cash proceeds from arya’s trust account, together with the proceeds from the pipe financing (as defined below), equaling no less than $250,000,000 (after deducting any amounts paid to arya shareholders that exercise their redemption rights in connection with the business combination and net of arya’s unpaid transaction expenses and arya’s unpaid liabilities), (ii) the approval by nasdaq of arya’s initial listing application in connection with the business combination, (iii) there being immediately following the closing of the business combination, to the knowledge of arya, no single beneficial owner of shares of arya common stock (other than the bain shareholder, the pfizer shareholder or the perceptive shareholder (each, as defined in the business combination agreement)) of greater than 9.9% and no three beneficial owners of shares of arya common stock (other than the bain shareholder, the pfizer shareholder and the perceptive shareholder) of greater than 25% and (iv) the consummation of the domestication. termination the business combination agreement may be terminated under certain customary and limited circumstances prior to the closing of the business combination, including, but not limited to, (i) by mutual written consent of arya and cerevel, (ii) by arya if the representations and warranties of cerevel are not true and correct or if cerevel fails to perform any covenant or agreement set forth in the business combination agreement such that certain conditions to closing cannot be satisfied and the breach or breaches of such representations or warranties or the failure to perform such covenant or agreement, as applicable, are not cured or cannot be cured within certain specified time periods, (iii) termination by cerevel if the representations and warranties of any arya party (as defined in the business combination agreement) are not true and correct or if any arya party fails to perform any covenant or agreement set forth in the business combination agreement such that certain conditions to closing cannot be satisfied and the breach or breaches of such representations or warranties or the failure to perform such covenant or agreement, as applicable, are not cured or cannot be cured within certain specified time periods, (iv) subject to certain limited exceptions, by either arya or cerevel if the business combination is not consummated by december 31, 2020, (v) by either arya or cerevel if certain required approvals are not obtained by arya shareholders after the conclusion of a meeting of arya’s stockholders held for such purpose at which such shareholders voted on such approvals, and (vi) termination by arya if the transaction support agreements (as described below) are not executed and delivered to arya within one business day of the signing date of the business combination agreement or if cerevel’s shareholders do not deliver to arya a written consent approving the business combination within two business days of the registration statement (as defined below) being declared effective under the securities act of 1933, as amended (the “securities act”). if the business combination agreement is validly terminated, none of the parties to the business combination agreement will have any liability or any further obligation under the business combination agreement other than customary confidentiality obligations, except in the case of willful breach or fraud (each, as defined in the business combination agreement). a copy of the business combination agreement is filed with this current report on form 8-k as exhibit 2.1 and is incorporated herein by reference, and the foregoing description of the business combination agreement is qualified in its entirety by reference thereto. the business combination agreement contains representations, warranties and covenants that the respective parties made to each other as of the date of the business combination agreement or other specific dates. the assertions embodied in those representations, warranties and covenants were made for purposes of the contract among the respective parties and are subject to important qualifications and limitations agreed to by the parties in connection with negotiating such agreement. the representations, warranties and covenants in the business combination agreement are also modified in important part by the underlying disclosure schedules which are not filed publicly and which are subject to a contractual standard of materiality different from that generally applicable to stockholders and were used for the purpose of allocating risk among the parties rather than establishing matters as facts. arya does not believe that these schedules contain information that is material to an investment decision. 3 sponsor letter agreement concurrently with the execution of the business combination agreement, arya, arya sciences holdings ii, a cayman islands exempted limited company (the “sponsor”), jake bauer, chad robins, todd wider and cerevel entered into the sponsor letter agreement (the “sponsor letter agreement”), pursuant to which the sponsor and each of jake bauer, chad robins and todd wider, as a holder of class b ordinary shares has agreed to, among other things, (i) vote in favor of the business combination agreement and the transactions contemplated thereby (including the merger), (ii) waive any adjustment to the conversion ratio set forth in the governing documents of arya or any other anti-dilution or similar protection with respect to the class b ordinary shares (whether resulting from the transactions contemplated by the subscription agreements (as defined below) or otherwise), (iii) be bound by certain other covenants and agreements related to the business combination and (iv) be bound by certain transfer restrictions with respect to his, her or its shares in arya prior to the closing of the business combination, in each case, on the terms and subject to the conditions set forth in the sponsor letter agreement. a copy of the sponsor letter agreement is filed with this current report on form 8-k as exhibit 10.1 and is incorporated herein by reference, and the foregoing description of the sponsor letter agreement is qualified in its entirety by reference thereto. pipe financing (private placement) concurrently with the execution of the business combination agreement, arya entered into subscription agreements (the “subscription agreements”) with certain investors, including, among others, perceptive life sciences master fund ltd, a fund managed by perceptive advisors, an affiliate of the sponsor, as well as certain equity holders of cerevel, including the pfizer shareholder and the bain shareholder. pursuant to the subscription agreements, each investor agreed to subscribe for and purchase, and arya agreed to issue and sell to such investors, on the closing date (as defined in the business combination agreement) immediately following the closing (as defined in the business combination agreement), an aggregate of 32,000,000 shares of arya common stock for a purchase price of $10.00 per share, for aggregate gross proceeds of $320,000,000 (the “pipe financing”). pursuant to the subscription agreement entered into with the bain shareholder (the “bain subscription agreement”), the bain shareholder may, subject to the cap specified therein, pre-fund a portion of its subscription amount by purchasing equity securities of cerevel prior to closing, the proceeds of which will be used to fund cerevel’s ongoing operations prior to completion of the business combination. the bain shareholder has, as of the date hereof, pre-funded $25,000,000 of its $100,000,000 subscription amount. the closing of the pipe financing is contingent upon, among other things, the substantially concurrent consummation of the business combination. the subscription agreements, including the bain subscription agreement, provide that arya will grant the investors in the pipe financing certain customary registration rights. the foregoing description of the subscription agreements, the bain subscription agreement and the pipe financing is subject to and qualified in its entirety by reference to the full text of the form of subscription agreement and the bain subscription agreement, copies of which are attached as exhibits 10.2 and 10.3 hereto, respectively, and the terms of which are incorporated herein by reference. cerevel transaction support agreements within one business day of the signing of the business combination agreement, each of the pfizer shareholder, the bain shareholder and the other shareholders of cerevel (collectively, the “cerevel shareholders”) entered into a transaction support agreement (collectively, the “transaction support agreements”) with arya, pursuant to which the cerevel shareholders have agreed to, among other things, (i) vote in favor of the business combination agreement and the transactions contemplated thereby, (ii) irrevocably appoint arya or any individual designated by arya as such cerevel shareholder’s agent, attorney-in-fact and proxy to attend on behalf of such cerevel shareholder any meeting of the cerevel shareholders with respect to the business combination and (iii) be bound by certain other covenants and agreements related to the business combination. the foregoing description of the transaction support agreements is subject to and qualified in its entirety by reference to the full text of the form of transaction support agreement, a copy of which is included as exhibit d to exhibit 2.1 hereto, and the terms of which are incorporated herein by reference. 4 arya shareholder support agreements concurrently with the execution of the subscription agreements, cerevel and certain holders of arya’s class a ordinary shares participating in the pipe financing entered into shareholder support agreements (the “shareholder support agreements”) pursuant to which each such holder agreed (i) to vote at any meeting of the shareholders of arya all of its ordinary shares held of record or thereafter acquired in favor of the business combination and the other transaction proposals (as defined in the business combination agreement), (ii) not to redeem any such securities in connection with the business combination, and (iii) to be bound by certain transfer restrictions with respect to such securities, unless (and only for the duration) that the trading price of arya’s class a ordinary shares on the nasdaq capital market exceeds $15.00 per share. investor rights agreement at the closing of the business combination, arya, the perceptive shareholders, the bain shareholder, the pfizer shareholder and certain other individuals will enter into an investor rights agreement (the “investor rights agreement”) pursuant to which, among other things, (i) the perceptive shareholders, the bain shareholder and the pfizer shareholder will agree not to effect any sale or distribution of arya equity securities during the lock-up period described therein, will be granted certain customary registration rights and will be granted certain preemptive rights and (ii) the bain shareholder and the pfizer shareholder agree to cast their votes such that the board of directors of arya, after the closing of the business combination, is constituted as set forth therein. the foregoing description of the investor rights agreement is subject to and qualified in its entirety by reference to the full text of the form of investor rights agreement, a copy of which is included as exhibit c to exhibit 2.1 hereto, and the terms of which are incorporated herein by reference. item 3.02 unregistered sales of equity securities. the disclosure set forth above in item 1.01 of this current report on form 8-k is incorporated by reference herein. the shares of arya common stock to be offered and sold in connection with the pipe financing have not been registered under the securities act in reliance upon the exemption provided in section 4(a)(2) thereof. item 7.01 regulation fd disclosure. on july 30, 2020, arya and cerevel issued a press release announcing their entry into the business combination agreement. the press release is attached hereto as exhibit 99.1 and incorporated by reference herein. furnished as exhibit 99.2 hereto and incorporated into this item 7.01 by reference is the investor presentation that arya and cerevel have prepared for use in connection with the announcement of the business combination. the foregoing (including exhibits 99.1 and 99.2) is being furnished pursuant to item 7.01 and will not be deemed to be filed for purposes of section 18 of the securities and exchange act of 1934, as amended (the “exchange act”), or otherwise be subject to the liabilities of that section, nor will it be deemed to be incorporated by reference in any filing under the securities act or the exchange act. additional information in connection with the business combination, arya intends to file with the u.s. securities and exchange commission’s (“sec”) a registration statement on form s-4 (the “registration statement”), which will include a preliminary prospectus and preliminary proxy statement. arya will mail a definitive proxy statement/final prospectus and other relevant documents to its shareholders. this communication is not a substitute for the registration statement, the definitive proxy statement/final prospectus or any other document that arya will send to its shareholders in connection with the business combination. investors and security holders of arya are advised to read, when available, the proxy statement/prospectus in connection with arya’s solicitation of proxies for its extraordinary general meeting of shareholders to be held to approve the business combination (and related matters) because the proxy statement/prospectus will contain important information about the business combination and the parties to the business combination. the definitive proxy statement/final prospectus will be mailed to shareholders of arya as of a record date to be established for voting on the business combination. shareholders will also be able to obtain copies of the proxy statement/prospectus, without charge, once available, at the sec’s website at www.sec.gov or by directing a request to: 51 astor place, 10th floor, new york, new york 10003. 5 participants in the solicitation arya, cerevel and their respective directors, executive officers, other members of management, and employees, under sec rules, may be deemed to be participants in the solicitation of proxies of arya’s shareholders in connection with the business combination. investors and security holders may obtain more detailed information regarding the names and interests in the business combination of arya’s directors and officers in arya’s filings with the sec, including the registration statement to be filed with the sec by arya, which will include the proxy statement of arya for the business combination, and such information and names of cerevel’s directors and executive officers will also be in the registration statement to be filed with the sec by arya, which will include the proxy statement of arya for the business combination. forward looking statements certain statements made herein are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the private securities litigation reform act of 1995. forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. these forward-looking statements include, but are not limited to, statements regarding future events, the business combination between arya and cerevel, the estimated or anticipated future results and benefits of the combined company following the business combination, including the likelihood and ability of the parties to successfully consummate the business combination, future opportunities for the combined company, and other statements that are not historical facts. these statements are based on the current expectations of arya’s management and are not predictions of actual performance. these forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. actual events and circumstances are difficult or impossible to predict and will differ from assumptions. many actual events and circumstances are beyond the control of arya and cerevel. these statements are subject to a number of risks and uncertainties regarding arya’s businesses and the business combination, and actual results may differ materially. these risks and uncertainties include, but are not limited to, general economic, political and business conditions; the inability of the parties to consummate the business combination or the occurrence of any event, change or other circumstances that could give rise to the termination of the business combination agreement; the outcome of any legal proceedings that may be instituted against the parties following the announcement of the business combination; the receipt of an unsolicited offer from another party for an alternative business transaction that could interfere with the business combination; the risk that the approval of the shareholders of arya or cerevel for the potential transaction is not obtained; failure to realize the anticipated benefits of the business combination, including as a result of a delay in consummating the potential transaction or difficulty in integrating the businesses of arya and cerevel; the risk that the business combination disrupts current plans and operations as a result of the announcement and consummation of the business combination; the ability of the combined company to grow and manage growth profitably and retain its key employees; the amount of redemption requests made by arya’s shareholders; the inability to obtain or maintain the listing of the post-acquisition company’s securities on nasdaq following the business combination; costs related to the business combination; and those factors discussed in arya’s final prospectus relating to its initial public offering, dated june 4, 2020, and other filings with the sec. there may be additional risks that arya presently does not know or that arya currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. in addition, forward-looking statements provide arya’s expectations, plans or forecasts of future events and views as of the date of this communication. arya anticipates that subsequent events and developments will cause arya’s assessments to change. however, while arya may elect to update these forward-looking statements at some point in the future, arya specifically disclaims any obligation to do so. these forward-looking statements should not be relied upon as representing arya’s assessments as of any date subsequent to the date of this communication. accordingly, undue reliance should not be placed upon the forward-looking statements. 6 disclaimer this communication is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities or the solicitation of any vote in any jurisdiction pursuant to the business combination or otherwise, nor shall there be any sale, issuance or transfer or securities in any jurisdiction in contravention of applicable law. no offer of securities shall be made except by means of a prospectus meeting the requirements of section 10 of the securities act. item 9.01 financial statements and exhibits. (d) exhibits exhibit number description 2.1† business combination agreement, dated as of july 29, 2020, by and among arya sciences acquisition corp ii, cassidy merger sub 1, inc. and cerevel therapeutics, inc. 10.1 sponsor letter agreement, dated as of july 29, 2020, by and among arya sciences holdings ii, certain other holders set forth on schedule i thereto, arya sciences acquisition corp ii and cerevel therapeutics, inc. 10.2 form of subscription agreement. 10.3 subscription agreement, by and between arya sciences acquisition corp ii and bc perception holdings, lp, dated july 29, 2020. 10.4 form of transaction support agreement (included as exhibit d to exhibit 2.1 hereto). 99.1 press release, dated july 30, 2020. 99.2 investor presentation. † certain of the exhibits and schedules to this exhibit have been omitted in accordance with regulation s-k item 601(b)(2). the registrant agrees to furnish supplementally a copy of all omitted exhibits and schedules to the sec upon its request. 7 signature pursuant to the requirements of the securities exchange act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. dated: july 30, 2020 arya sciences acquisition corp ii by: /s/ adam stone name: adam stone title: chief executive officer 8 ",https://www.sec.gov/Archives/edgar/data/1805387/000114036120017009/0001140361-20-017009-index.htm,8-K,2020-07-30 07:51:41
2020-07-22," 8-k 1 nc10013644x1_8k.htm form 8-k united states securities and exchange commission washington, d.c. 20549 form 8-k current report pursuant to section 13 or section 15(d) of the securities exchange act of 1934 date of report (date of earliest event reported): july 22, 2020 arya sciences acquisition corp ii (exact name of registrant as specified in its charter) cayman islands (state or other jurisdiction of incorporation or organization) 001-39311 (commission file number) 98-1533670 (irs employer identification number) 51 astor place, 10th floor new york, ny 10003 (address of principal executive offices) (212) 284-2300 registrant’s telephone number, including area code not applicable (former name or former address, if changed since last report) check the appropriate box below if the form 8-k filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions: ☐ written communications pursuant to rule 425 under the securities act (17 cfr 230.425) ☐ soliciting material pursuant to rule 14a-12 under the exchange act (17 cfr 240.14a-12) ☐ pre-commencement communications pursuant to rule 14d-2(b) under the exchange act (17 cfr 240.14d-2(b)) ☐ pre-commencement communications pursuant to rule 13e-4(c) under the exchange act (17 cfr 240.13e-4(c)) securities registered pursuant to section 12(b) of the act: title of each class trading symbol(s) name of each exchange on which registered units, each consisting of one class a ordinary share, $0.0001 par value, and one-third of one redeemable warrant arybu the nasdaq capital market class a ordinary shares included as part of the units aryb the nasdaq capital market redeemable warrants included as part of the units, each whole warrant exercisable for one class a ordinary share at an exercise price of $11.50 arybw the nasdaq capital market indicate by check mark whether the registrant is an emerging growth company as defined in rule 405 of the securities act of 1933 or rule 12b-2 of the securities exchange act of 1934. emerging growth company ☒ if an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the exchange act. ☐ item 8.01. other events. on july 22, 2020, arya sciences acquisition corp ii (the “company”) announced that the holders of the company’s units (the “units”) may elect to separately trade the class a ordinary shares, par value $0.0001 per share (“class a ordinary shares”), and redeemable warrants included in the units commencing on july 24, 2020. each unit consists of one class a ordinary share and one-third of one redeemable warrant to purchase one class a ordinary share. any units not separated will continue to trade on the the nasdaq capital market (“nasdaq”) under the symbol “arybu”. any underlying class a ordinary shares and warrants that are separated will trade on nasdaq under the symbols “aryb” and “arybw,” respectively. no fractional warrants will be issued upon separation of the units and only whole warrants will trade. holders of units will need to have their brokers contact continental stock transfer & trust company, the company’s transfer agent, in order to separate the holders’ units into class a ordinary shares and warrants. a copy of the press release issued by the company announcing the separate trading of the securities underlying the units is attached hereto as exhibit 99.1. item 9.01. financial statements and exhibits. (d) exhibits. exhibit no. description 99.1 press release, dated july 22, 2020. signature pursuant to the requirements of the securities exchange act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. dated: july 22, 2020 arya sciences acquisition corp ii by: /s/ adam stone name: adam stone title: chief executive officer ",https://www.sec.gov/Archives/edgar/data/1805387/000114036120016538/0001140361-20-016538-index.htm,8-K,2020-07-22 16:44:00
2020-06-15," 8-k 1 nc10012774x1_8k.htm form 8-k united states securities and exchange commission washington, dc 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of report (date of earliest event reported): june 9, 2020 arya sciences acquisition corp ii (exact name of registrant as specified in its charter) cayman islands (state or other jurisdiction of incorporation or organization) 001-39311 (commission file number) 98-1533670 (irs employer identification no.) 51 astor place, 10th floor new york, ny (address of principal executive offices) 10003 (zip code) (212) 284-2300 registrant’s telephone number, including area code not applicable (former name or former address, if changed since last report) check the appropriate box below if the form 8-k filing is intended to simultaneously satisfy the filing obligation of the registrant under anyof the following provisions: ☐ written communications pursuant to rule 425 under the securities act (17 cfr 230.425) ☐ soliciting material pursuant to rule 14a-12 under the exchange act (17 cfr 240.14a-12) ☐ pre-commencement communications pursuant to rule 14d-2(b) under the exchange act (17 cfr 240.14d-2(b)) ☐ pre-commencement communications pursuant to rule 13e-4(c) under the exchange act (17 cfr 240.13e-4(c)) securities registered pursuant to section 12(b) of the act: title of each class trading symbol(s) name of each exchange on which registered units, each consisting of one class a ordinary share, $0.0001 par value, and one-third of one redeemable warrant arybu the nasdaq capital market class a ordinary shares included as part of the units aryb the nasdaq capital market redeemable warrants included as part of the units, each whole warrant exercisable for one class a ordinary share at an exercise price of $11.50 arybw the nasdaq capital market indicate by check mark whether the registrant is an emerging growth company as defined in rule 405 of the securities act of 1933 or rule 12b-2 of the securities exchange act of 1934. emerging growth company ☒ if an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the exchange act. ☐ item 8.01. entry into a material definitive agreement. on june 9, 2020, arya sciences acquisition corp ii (the “company”) consummated an initial public offering (the “ipo”) of 14,950,000 units (the “units”), including the 1,950,000 units as a result of the underwriters’ full exercise of their over-allotment option, at an offering price of $10.00 per unit and a private placement with arya sciences holdings ii of 499,000 private placement units, each private placement unit consisting of one class a ordinary share and one-third of one redeemable warrant, each whole warrant exercisable to purchase one class a ordinary share at $11.50 per share, subject to adjustment, at a price of $10.00 per private placement unit (the “private placement”). the net proceeds from the ipo, together with certain of the proceeds from the private placement, $149,500,000 in the aggregate (the “offering proceeds”), were placed in a trust account established for the benefit of the company’s public shareholders and the underwriters of the ipo with continental stock transfer & trust company acting as trustee. except with respect to interest earned on the offering proceeds held in the trust account that may be released to the company to pay its income taxes, if any, the company’s amended and restated memorandum and articles of association will provide that the offering proceeds will not be released from the trust account (1) to the company, until the completion of its initial business combination, or (2) to its public shareholders, until the earliest of (a) the completion of the its initial business combination, and then only in connection with those class a ordinary shares that such shareholders properly elected to redeem, subject to certain limitations, (b) the redemption of any public shares properly tendered in connection with a shareholder vote to amend the company’s amended and restated memorandum and articles of association (a) to modify the substance or timing of the company’s obligation to provide holders of its class a ordinary shares the right to have their shares redeemed in connection with the company’s initial business combination or to redeem 100% of its public shares if the company does not complete its initial business combination within 24 months from the closing of the ipo or (b) with respect to any other provision relating to the rights of holders of its class a ordinary shares, and (c) the redemption of the public shares if the company has not consummated its business combination within 24 months from the closing of the ipo, subject to applicable law. an audited balance sheet as of june 9, 2020 reflecting receipt of the offering proceeds has been issued by the company and is included as exhibit 99.1 to this current report on form 8-k. item 9.01. financial statements and exhibits. (d) exhibits 99.1 audited balance sheet signature pursuant to the requirements of the securities exchange act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. dated: june 15, 2020 arya sciences acquisition corp ii by: /s/ adam stone name: adam stone title: chief executive officer ",https://www.sec.gov/Archives/edgar/data/1805387/000114036120013787/0001140361-20-013787-index.htm,8-K,2020-06-15 16:55:21
2020-06-09," 8-k 1 nt10009663x11_8k.htm form 8k united states securities and exchange commission washington, dc 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of report (date of earliest event reported): june 9, 2020 arya sciences acquisition corp ii (exact name of registrant as specified in its charter) cayman islands 001-39311 98-1533670 (state or other jurisdiction (commission (irs employer of incorporation or organization) file number) identification no.) 51 astor place, 10th floor new york, ny 10003 (address of principal executive offices) (zip code) (212) 284-2300 registrant’s telephone number, including area code not applicable (former name or former address, if changed since last report) check the appropriate box below if the form 8-k filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ written communications pursuant to rule 425 under the securities act (17 cfr 230.425) ☐ soliciting material pursuant to rule 14a-12 under the exchange act (17 cfr 240.14a-12) ☐ pre-commencement communications pursuant to rule 14d-2(b) under the exchange act (17 cfr 240.14d-2(b)) ☐ pre-commencement communications pursuant to rule 13e-4(c) under the exchange act (17 cfr 240.13e-4(c)) securities registered pursuant to section 12(b) of the act: trading name of each exchange on title of each class symbol(s) which registered units, each consisting of one class a ordinary share, $0.0001 par value, and one-third of one redeemable warrant arybu the nasdaq capital market class a ordinary shares included as part of the units aryb the nasdaq capital market redeemable warrants included as part of the units, each whole warrant exercisable for one class a ordinary share at an exercise price of $11.50 arybw the nasdaq capital market indicate by check mark whether the registrant is an emerging growth company as defined in rule 405 of the securities act of 1933 or rule 12b-2 of the securities exchange act of 1934. emerging growth company ☒ if an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the exchange act. ☐ item 1.01. entry into a material definitive agreement. on june 4, 2020, the registration statement on form s-1 (file no. 333-238488) (the “registration statement”) relating to the initial public offering (the “ipo”) of arya sciences acquisition corp ii (the “company”) was declared effective by the u.s. securities and exchange commission, and the company subsequently filed, on june 4, 2020, a registration statement on form s-1 (file no. 333-238949) pursuant to rule 462(b) under the securities act of 1933, as amended, which was effective immediately upon filing. on june 9, 2020 the company consummated the ipo of 14,950,000 units (the “units”), which includes the exercise in full of the underwriters’ option to purchase an additional 1,950,000 units at the initial public offering price to cover over-allotments. each unit consists of one class a ordinary share, $0.0001 par value per share (the “class a ordinary shares”), and one-third of one redeemable warrant (the “public warrants”), each whole public warrant entitling the holder thereof to purchase one class a ordinary share at an exercise price of $11.50 per share, subject to adjustment. the units were sold at an offering price of $10.00 per unit, generating gross proceeds of $149,500,000. further, in connection with the ipo, the company entered into the following agreements, forms of which were previously filed as exhibits to the registration statement: • an underwriting agreement, dated june 4, 2020, among the company and jefferies llc and goldman sachs & co. llc, as representatives of the underwriters named in schedule a therein, which contains customary representations and warranties and indemnification of the underwriter by the company; • a private placement units purchase agreement, dated june 4, 2020, between the company and arya sciences holdings ii (the “sponsor”), pursuant to which the sponsor purchased 499,000 private placement units (the “private placement units”), each private placement unit consisting of one class a ordinary share and one-third of one redeemable warrant, each whole private placement warrant entitling the holder thereof to purchase one class a ordinary share at $11.50 per share, subject to adjustment (the “private placement warrants” and, together with the public warrants, the “warrants”), at a price of $10.00 per private placement unit; • a warrant agreement, dated june 9, 2020, between the company and continental stock transfer & trust company, as warrant agent (the “warrant agreement”), which sets forth the expiration and exercise price of and procedure for exercising the warrants; certain adjustment features of the terms of exercise; provisions relating to redemption and cashless exercise of the warrants; certain registration rights of the holders of warrants; provision for amendments to the warrant agreement; and indemnification of the warrant agent by the company under the agreement; • an investment management trust agreement, dated june 9, 2020, between the company and continental stock transfer & trust company, as trustee, which establishes the trust account that will hold the net proceeds of the ipo and certain of the proceeds of the sale of the private placement units, and sets forth the responsibilities of the trustee; the procedures for withdrawal and direction of funds from the trust account; and indemnification of the trustee by the company under the agreement; • a registration and shareholder rights agreement, dated june 9, 2020, among the company, the sponsor and certain equityholders of the company, which provides for customary demand and piggy-back registration rights for the sponsor, and customary piggy-back registration rights for such other equityholders, and, upon and following consummation of our initial business combination, the right of the sponsor to nominate three individuals for election to the company’s board of directors; • letter agreement, dated june 4, 2020, among the company, the sponsor and each executive officer and director of the company, pursuant to which each of the sponsor and each executive officer and director of the company has agreed to vote any class a ordinary shares held by him, her or it in favor of the company’s initial business combination; to facilitate the liquidation and winding up of the company if an initial business combination is not consummated within 24 months of the date hereof; to certain transfer restrictions with respect to the company’s securities; to certain indemnification obligations of the sponsor; and the company has agreed not to enter into a definitive agreement regarding an initial business combination without the prior consent of the sponsor; and • an administrative services agreement, dated june 9, 2020, between the company and the sponsor, pursuant to which the sponsor has agreed to make available office space, secretarial and administrative services, as may be required by the company from time to time, for $10,000 per month until the earlier of the company’s completion of its initial business combination or liquidation. the above descriptions are qualified in their entirety by reference to the full text of the applicable agreement, each of which is incorporated by reference herein and filed herewith as exhibits 1.1, 10.1, 4.1, 10.2, 10.3, 10.4 and 10.5, respectively. item 3.02. unregistered sales of equity securities. simultaneous with the consummation of the ipo and the issuance and sale of the units, the company consummated the private placement of 499,000 private placement units at a price of $10.00 per private placement unit, generating total proceeds of $4,990,000 (the “private placement”). the private placement warrants included in the private placement units purchased by the sponsor are substantially similar to the public warrants, except that if held by the sponsor or its permitted transferees, they (i) may be exercised for cash or on a cashless basis, (ii) are not subject to being called for redemption (except in certain circumstances when the public warrants are called for redemption and a certain price per class a ordinary share threshold is met) and (iii) subject to certain limited exceptions including the class a ordinary shares issuable upon exercise of the private placement warrants, will be subject to transfer restrictions until 30 days following the consummation of the company’s initial business combination. if the private placement warrants are held by holders other than the sponsor or its permitted transferees, the private placement warrants will be redeemable by the company in all redemption scenarios and exercisable by holders on the same basis as the public warrants. the private placement units have been issued pursuant to the private placement units purchase agreement and the private placement warrants have been issued pursuant to, and are governed by the warrant agreement. item 5.03. amendments to memorandum and articles of association. on june 4, 2020 and in connection with the ipo, the company adopted its amended and restated memorandum and articles of association. the amended and restated memorandum and articles of association is filed herewith as exhibit 3.1 and is incorporated by reference herein. item 9.01. financial statements and exhibits. (d) exhibits 1.1 underwriting agreement among the company, jefferies llc and goldman sachs & co. llc 3.1 amended and restated memorandum and articles of association 4.1 warrant agreement between continental stock transfer & trust company and the company 10.1 private placement units purchase agreement between the company and the sponsor 10.2 investment management trust agreement between continental stock transfer & trust company and the company 10.3 registration and shareholder rights agreement among the company, the sponsor and certain other equityholders named therein 10.4 letter agreement among the company, the sponsor and the company’s officers and directors 10.5 administrative services agreement between the company and the sponsor signature pursuant to the requirements of the securities exchange act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. dated: june 9, 2020 arya sciences acquisition corp ii by: /s/ adam stone name: adam stone title: chief executive officer ",https://www.sec.gov/Archives/edgar/data/1805387/000114036120013438/0001140361-20-013438-index.htm,8-K,2020-06-09 17:15:42
